How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence

Dominik J. Wettstein and Stefan Boes

Health Policy, 2022, vol. 126, issue 2, 112-121

Abstract: Various forms of value-based pricing policies for new medicines have recently been introduced in OECD countries. While these initiatives are expected to have a positive impact on societal outcomes such as availability, affordability and value for money, scientific evidence on this impact is scarce due to confidential agreements.

Keywords: Pharmaceutical policies; Pharmaceutical pricing; Pharmaceutical pricing policies; Drug pricing; Access to medicines; Laboratory experiment (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851021003109
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:126:y:2022:i:2:p:112-121

DOI: 10.1016/j.healthpol.2021.12.007

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().